Oxford, UK – 3 November 2014: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE:OXB), a leading gene and cell therapy company, today publishes its interim management statement for the period from 1 July to 31 October 2014. Read More
Oxford, UK – 13 October 2014: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE:OXB), a leading gene and cell therapy company, announces that it has acquired the freehold of the Windrush Court office and laboratory facilities in… Read More
Oxford, UK – 10 October 2014: Oxford BioMedica plc (LSE:OXB), (“Oxford Biomedica” or “the Group”) a leading gene and cell therapy company, announces today that it has signed further contracts with Novartis which build on the collaboration with… Read More
Oxford, UK – 28 August 2014: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE:OXB), a world-leading gene and cell therapy company, today announces its unaudited interim results for the six months ended 30 June 2014. Read More
— Dr Paul Blake to take Executive Role as Chief Development Officer — Oxford, UK – 15 August 2014: Oxford BioMedica plc (LSE:OXB), (“Oxford Biomedica”… Read More
Oxford, UK – 23 June 2014: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE:OXB), the leading gene-based biopharmaceutical company, today announces that it will attend Piper Jaffray’s GenomeRx Symposium on Monday, June 23, 2014 at The Yale… Read More
Oxford, UK – 18 June 2014: Oxford BioMedica (“the Company”) (LSE:OXB), the leading gene-based biopharmaceutical company, announces that the Company has repaid in full the amount drawn down from the £5 million secured loan facility agreement, agreed on… Read More
Oxford, UK – 03 June 2014: Oxford BioMedica (“the Company”) (LSE:OXB), the leading gene-based biopharmaceutical company, announced today that all resolutions proposed were duly passed at its Annual General Meeting (AGM), held today in London. Read More
Oxford, UK – 13 May 2014: Oxford BioMedica plc (LSE:OXB), (“the Company”) the leading gene based biopharmaceutical company, today publishes its interim management statement for the period 1 January to 12 May 2014. OPERATIONAL HIGHLIGHTSLentiVector® platform product development Ocular portfolio… Read More
£2.2M award will be used to fund a Phase I/II clinical trial of Oxford Biomedica-102, an enhanced version of ProSavin®; a gene therapy for the treatment of Parkinson’s disease … Read More
Oxford, UK – 29 April 2014: Oxford BioMedica plc (LSE:OXB), (“the Company”) the leading gene based biopharmaceutical company, announces that it will regain the worldwide rights to RetinoStat… Read More
Click here to download the full 2013 Preliminary Results Statement.Click here to download the 2013 Results Presentation.Click here to… Read More